Glucagon/GLP-1 receptor co-agonists

• US 8,729,017 B2
• Filed: 06/12/2012
• Issued: 05/20/2014
• Est. Priority Date: 06/22/2011
• Status: Expired due to Fees

• Current Assignee: Indiana University Research & Technology Corporation (Indiana University)
• Original Assignee: Indiana University Research & Technology Corporation (Indiana University)
• Inventors: DiMarchi, Richard D., Smiley, David L., Yang, Bin
• Primary Examiner(s): Chandra, Gyan
• Application Number:
  US13/494,480
• Publication Number:
  US 20120329707A1
• Time in Patent Office: 707 Days
• Field of Search: None
• US Class Current: 514/7.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/605 Glucagons
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: G01N 2333/605 Glucagons
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 2800/085 Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 2800/2835 Movement disorders, e.g. Parkinson, Huntington, Tourette
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.

Claims

1. An isolated peptide comprising:

(a) the amino acid sequence of SEQ ID NO;

37;

(b) or a variant peptide thereof, wherein the variant peptide comprises;

(i) an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO;

37 wherein the variant peptide exhibits enhanced activity at the GLP-1 receptor, as compared to native glucagon, and exhibits at least 100-fold selectivity for the human GLP-1 receptor versus the GIP receptor, or

(ii) an amino acid sequence based on SEQ ID NO;

37, but differs in one or more of the following ways;

a. the variant peptide comprises an acylated amino acid or an alkylated amino acid;

b. an acylated amino acid or an alkylated amino acid is replaced with the corresponding amino acid of native glucagon (SEQ ID NO;

     1) at that position or a conservative substitution of the native amino acid, and optionally a new acylated or alkylated amino acid is introduced at a different position;

c. the variant peptide comprises an amino acid covalently attached to a hydrophilic moiety;

d. an amino acid covalently attached to a hydrophilic moiety is replaced with the corresponding amino acid of native glucagon (SEQ ID NO;

     1) at that position, and optionally a new amino acid covalently attached to a hydrophilic moiety is introduced at a different position;

e. the C-terminal amino acid of the variant peptide comprises a C-terminal amide in place of a C-terminal alpha carboxylate;

f. an amino acid at any of positions 1 through 29 is replaced with the corresponding amino acid of native glucagon (SEQ ID NO;

     1) at that position;

or

g. or any combinations thereof;

or a pharmaceutically acceptable salt of the peptide or variant peptide.

2. The variant peptide of claim 1, comprising (i) a hydrophilic moiety covalently attached to an amino acid at position 16, 17, 21, 24, 29, a position within a C-terminal extension, or at the C-terminus, (ii) a hydrophilic moiety covalently attached to an amino acid selected from the group consisting of:

Cys, Lys, Orn, homocysteine, and Ac-Phe, (iii) or a combination thereof.

3. The variant peptide of claim 2, wherein the hydrophilic moiety is a polyethylene glycol, optionally, a PEG of molecular weight between 10 kDa and 40 kDa.

4. The variant peptide of claim 1, comprising (i) an acylated or alkylated amino acid at position 10, (ii) an acylated or alkylated amino acid which is an acylated or alkylated amino acid of Formula I, Formula II, or Formula III, optionally, wherein the amino acid of Formula I is Lys, or (iii) an acylated or alkylated amino acid, wherein the acyl group or alkyl group is covalently attached to the amino acid via a spacer, optionally, wherein the spacer is an amino acid or a dipeptide.

5. The variant peptide of claim 4, comprising an acylated or alkylated amino acid which comprises a C8 to C20 alkyl chain, a C12 to C18 alkyl chain, or a C14 or C16 alkyl chain.

6. The variant peptide of claim 4, wherein the spacer comprises one or two acidic residues.

7. The peptide or variant peptide of claim 1, wherein the (EC50 at the glucagon receptor)/(EC50 at the GLP-1 receptor) is about 20 or less.

8. A conjugate comprising a peptide or variant peptide of claim 1 conjugated to a heterologous moiety.

9. The conjugate of claim 8, wherein the heterologous moiety comprises one or more of:

a peptide, a polypeptide, a nucleic acid molecule, an antibody or fragment thereof, a polymer, a quantum dot, a small molecule, a toxin, a diagnostic agent.

10. The conjugate of claim 9, comprising an extension of 1-21 amino acids C-terminal to the amino acid at position 29 or the peptide or variant peptide.

11. The conjugate of claim 10, wherein the extension is selected from the group consisting of:

Gly, Glu, Cys, Gly-Gly, Gly-Glu, GPSSGAPPPS (SEQ ID NO;

     9) or GGPSSGAPPPS (SEQ ID NO;

     10).

12. The conjugate of claim 8, wherein the heterologous moiety comprises one or more of:

a peptide, a polypeptide, a nucleic acid molecule, an antibody or fragment thereof, a polymer, a quantum dot, a small molecule, a toxin, a diagnostic agent.

13. A dimer or multimer comprising a peptide or variant peptide of claim 1.

14. A pharmaceutical composition comprising the peptide or variant peptide of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. A method of treating a disease or medical condition in a patient in need thereof, wherein the disease or medical condition is selected from the group consisting of:

metabolic syndrome, diabetes, obesity, and liver steatosis, comprising administering to the patient the pharmaceutical composition of claim 14 in an amount effective to treat the disease or medical condition.

16. The pharmaceutical composition of claim 14, further comprising an anti-diabetes agent or anti-obesity agent.

17. The pharmaceutical composition of claim 16, wherein the anti-diabetic agent is insulin, leptin, Peptide YY (PYY), Pancreatic Peptide (PP), fibroblast growth factor 21 (FGF21), Y2Y4 receptor agonists, sulfonylureas, such as tolbutamide (Orinase), acetohexamide (Dymelor), tolazamide (Tolinase), chlorpropamide (Diabinese), glipizide (Glucotrol), glyburide (Diabeta, Micronase, Glynase), glimepiride (Amaryl), or gliclazide (Diamicron);

meglitinides, such as repaglinide (Prandin) or nateglinide (Starlix);

biguanides such as metformin (Glucophage) or phenformin;

thiazolidinediones such as rosiglitazone (Avandia), pioglitazone (Actos), or troglitazone (Rezulin), or other PPARγ

inhibitors;

alpha glucosidase inhibitors that inhibit carbohydrate digestion, such as miglitol (Glyset), acarbose (Precose/Glucobay);

exenatide (Byetta) or pramlintide;

Dipeptidyl peptidase-4 (DPP-4) inhibitors such as vildagliptin or sitagliptin;

SGLT (sodium-dependent glucose transporter

     1) inhibitors;

glucokinase activators (GKA);

glucagon receptor antagonists (GRA);

or FBPase (fructose 1,6-bisphosphatase) inhibitors.

18. The pharmaceutical composition of claim 16, wherein the anti-obesity agent is appetite suppressants, including phenethylamine type stimulants, phentermine (optionally with fenfluramine or dexfenfluramine), diethylpropion, phendimetrazine, benzphetamine, sibutramine;

rimonabant, other cannabinoid receptor antagonists;

oxyntomodulin;

fluoxetine hydrochloride;

topiramate and phentermine, bupropion and zonisamide or bupropion and naltrexone;

or lipase inhibitors, similar to Orlistat or Cetilistat (also known as ATL-962).

19. An isolated peptide comprising the amino acid sequence of SEQ ID NO:

37.

20. A conjugate comprising the peptide of claim 19 conjugated to a heterologous moiety.

21. A pharmaceutical composition comprising the peptide of claim 19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

22. A method of treating a disease or medical condition in a patient in need thereof, wherein the disease or medical condition is selected from the group consisting of:

metabolic syndrome, diabetes, obesity, and liver steatosis, comprising administering to the patient the pharmaceutical composition of claim 21 in an amount effective to treat the disease or medical condition.

23. The pharmaceutical composition of claim 21, further comprising an anti-diabetes agent or anti-obesity agent.